Scientific Publications by FDA Staff
Infect Immun 2007 Jun;75(6):2689-98
A Murine Aerosol Challenge Model of Anthrax.
Loving CL, Kennett M, Lee GM, Grippe VK, Merkel TJ
Merkel TJ (reprint author), CBER, Lab Resp & Special Pathogens, DBPAP, FDA, Bld 29,Room 418,29 Lindoln Dr,880 Rockville Pike, Bethesda, MD 20892 USA CBER, Lab Resp & Special Pathogens, DBPAP, FDA, Bethesda, MD 20892 USA Penn State Univ, Dept Vet & Bimed Sci, State Coll, PA 16804 USA
The availability of relevant and useful animal models is critical for progress in the development of effective vaccines and therapeutics. The infection of rabbits and non-human primates with fully virulent Bacillus anthracis spores provides two excellent models of anthrax disease. However, the high cost of procuring and housing these animals, and the specialized facilities required to deliver fully virulent spores, limits their practical use in early stages of product development. Conversely, the small size and low cost associated with using mice makes this animal model more practical for conducting experiments in which large numbers of animals are required. In addition, the availability of knock-out strains and well-characterized immunological reagents makes it possible to perform studies in mice that cannot be performed easily in other species. Although we, and others, have used the mouse aerosol challenge model to examine the outcome of B. anthracis infection, a detailed characterization of the disease is lacking. The current study utilizes a murine aerosol challenge model to investigate disease progression, innate cytokine responses and histological changes during the course of anthrax after challenge with aerosolized spores. Our results show that anthrax disease progression in a complement-deficient mouse after challenge with aerosolized Sterne spores is similar to that described for other species, including rabbits and non-human primates, challenged with fully virulent B. anthracis. Thus, the murine aerosol challenge model is both useful and relevant, and provides a means to further investigate the host response and mechanisms of B. anthracis pathogenesis.
|Category: Journal Article|
|PubMed ID: #17353290|
|Includes FDA Authors from Scientific Area(s): Biologics|
|Entry Created: 2011-10-04||Entry Last Modified: 2012-08-29|